Hinova Today Listed on the Science and Technology Innovation Board (the “STAR Market”) of the Shanghai Stock Exchange (SSE) in China, Relying on PROTAC and Deuterium Technology to Develop Innovative D
On April 12, 2022, Hinova Pharmaceuticals Inc. was successfully listed on the Science and Technology Innovation Board (the “STAR” Market) of the Shanghai Stock Exchange (SSE). The proposed issue of 24.76 million shares of Hinova was intended to raise funds for innovative drug research, research & development and production base construction and future development.
About Hinova
Hinova is an international and clinical-stage biopharmaceutical company focusing on developing novel therapeutics for cancers and metabolic diseases. Hinova has committed to the discovery and development of innovative medicines for patients globally through deuteration and targeted protein degradation technologies. The company has 4 clinical-stage programs: HC-1119, a deuterated compound of enzalutamide, for the treatment of men with mCRPC; HP501, an URAT1 inhibitor, for hyperuricemia and gout treatment；HP558, a First-in-class CD44v6 inhibitor, for esophageal squamous cell carcinoma treatment; and HP518, an oral AR PROTAC, with the potential to solve the drug resistance in prostate cancer caused by AR mutation. For more information, please visit http://eambuy.com.cn/en/.
- Hinova's Clinical Trial Application for the Combination of HP501 Sustained-release Tablets and xanthine oxidase inhibitors in the Treatment of Hyperuricemia/Gout was Accepted by NMPA
- Hinova Receives FDA Proceed Authorization for its IND Application for HP518, an Orally Bioavailable Chimeric Degrader Targeting Androgen Receptor for Prostate Cancer Treatment
- Hinova Disclosed the Preclinical Results of HP518 (Oral AR PROTAC) at the 5th Annual TPD Summit
- Hinova Announces Phase III Clinical Trial of Deutenzalutamide (HC-1119) in Chinese Patients with castration-resistant prostate cancer (mCRPC) Met Primary Endpoint
- Hinova Today Listed on the Science and Technology Innovation Board (the “STAR Market”) of the Shanghai Stock Exchange (SSE) in China, Relying on PROTAC and Deuterium Technology to Develop Innovative D
